Overview

Fenofibrate in Type 2 Diabetes

Status:
Completed
Trial end date:
2020-03-04
Target enrollment:
Participant gender:
Summary
Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopathy offers an important translational research opportunity. The investigator's global proteomic study will provide new clues as to how fenofibrate protects vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of South Carolina
Treatments:
Fenofibrate